Soc. Generale Call 25 SDZ 20.06.2.../ DE000SW8Q6N4 /
| 9/5/2024 9:40:32 PM | Chg.0.000 | Bid9/5/2024 | Ask9/5/2024 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.150EUR | 0.00% | 1.150 Bid Size: 6,000 |
1.260 Ask Size: 6,000 |
SANDOZ GROUP N | 25.00 CHF | 6/20/2025 | Call |
GlobeNewswire
8/12
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
7/25
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire
7/1
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire
5/22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
4/30
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
4/30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
4/22
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
3/21
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire
3/4
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
2/29
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire
1/31
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire
1/22
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
11/21/2023
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
